<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536263</url>
  </required_header>
  <id_info>
    <org_study_id>P05170</org_study_id>
    <nct_id>NCT00536263</nct_id>
  </id_info>
  <brief_title>PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)</brief_title>
  <official_title>An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron
      for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the
      approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks.
      This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg
      once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks
      after their treatment ends.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss</measure>
    <time_frame>24 weeks after end of treatment (EOT)</time_frame>
    <description>HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBeAg Loss</measure>
    <time_frame>Up to Treatment Week 48</time_frame>
    <description>HBeAg Loss was tested by assay of Abbott MEIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBe Seroconversion</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) &lt;20,000 IU/mL</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test
lowest limit is 6 IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBV-DNA &lt; 200 IU/mL</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBV-DNA Undetectable</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>Undetectable HBV-DNA was defined as having a level &lt;6 IU/mL by polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Biochemical Response</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>Biochemical response was defined as alanine aminotransferase (ALT) normalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Combined Response</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>Combined response was defined as HBV DNA &lt;20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Surface Antigen (HBsAg) Loss</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>HBsAg Loss was tested by assay of Abbott MEIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Surface Antigen (HBs) Seroconversion</measure>
    <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
    <description>HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Biopsy Score</measure>
    <time_frame>Baseline to 24 weeks after end of treatment</time_frame>
    <description>Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System):
Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis).
Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked [involvement of &gt;2/3 of lobules or nodules]).
Score III (portal inflammation): 0 (none) to 4 (Marked [dense packing of
inflammatory cells in &gt;2/3 of portal tracts]).
Score IV (fibrosis): 0 (none) to 4 (cirrhosis).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">671</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>PEG 1.0 mcg/kg weekly (QW) * 24 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 1.5 mcg/kg QW * 24 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 1.5 mcg/kg QW * 48 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha-2b</intervention_name>
    <description>1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks</description>
    <arm_group_label>PEG 1.0 mcg/kg weekly (QW) * 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha-2b</intervention_name>
    <description>1.5 mcg/kg S.C. QW for 24 weeks</description>
    <arm_group_label>PEG 1.5 mcg/kg QW * 24 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha-2b</intervention_name>
    <description>1.5 mcg/kg S.C. QW for 48 weeks</description>
    <arm_group_label>PEG 1.5 mcg/kg QW * 48 wks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with chronic hepatitis B:

               -  Serum hepatitis B surface antigen positive for at least 6 months

               -  Serum hepatitis B e antigen positive

               -  Serum negative for hepatitis B surface and e antibodies

               -  Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000
                  IU/mL

               -  Alanine aminotransferase (ALT) 2- to 10-times the upper limit of normal

          -  Compensated liver disease with certain minimum hematological and serum biochemical
             criteria

        Exclusion Criteria:

          -  Significant hepatic disease from an etiology other than hepatitis B virus

          -  Antiviral treatment for hepatitis within previous 6 months

          -  History of severe psychiatric disease, especially depression

          -  Unstable or significant cardiovascular disease

          -  Prolonged exposure to known hepatotoxins such as alcohol or drugs

          -  Any condition that could interfere with the subject participating in and completing
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>China</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </removed_countries>
  <results_reference>
    <citation>Cheng J, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Mohamed R, Guan R, Lee TH, Chang WH, Zhenfei H, Ye Z, Xu D. Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial. J Clin Virol. 2014 Dec;61(4):509-16. doi: 10.1016/j.jcv.2014.08.008. Epub 2014 Aug 18.</citation>
    <PMID>25200354</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <results_first_submitted>November 23, 2010</results_first_submitted>
  <results_first_submitted_qc>November 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2010</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
          <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
        </group>
        <group group_id="P2">
          <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
          <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
        </group>
        <group group_id="P3">
          <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
          <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="225">One (1) participant withdrawn from study for non-compliance.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew - not treatment related</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew - treatment related</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG 1.0 mcg/kg QW * 24 Weeks</title>
          <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up; treated participants</description>
        </group>
        <group group_id="B2">
          <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
          <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up; treated participants</description>
        </group>
        <group group_id="B3">
          <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
          <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up; treated participants.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="224"/>
            <count group_id="B4" value="670"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Treated Participants</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="7.2"/>
                    <measurement group_id="B2" value="27.5" spread="7.1"/>
                    <measurement group_id="B3" value="28.4" spread="7.6"/>
                    <measurement group_id="B4" value="28.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Treated Participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss</title>
        <description>HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)</description>
        <time_frame>24 weeks after end of treatment (EOT)</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss</title>
          <description>HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in the proportion with HBeAg loss.
Based on the targeted sample size, there was 80% statistical power (2-sided 0.05 alpha) to detect a true 36% HBeAg loss rate in this treatment arm versus a true rate of 23% in the control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <p_value_desc>P-values are unadjusted; Hochberg’s adjustment for multiple comparisons was used to maintain the overall 0.05 significance level in test of superiority using the Cochran-Mantel-Haenszel test.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.079</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in the proportion with HBeAg loss.
Based on the targeted sample size, there was 80% statistical power (2-sided 0.05 alpha) to detect a true 36% HBeAg loss rate in this treatment arm versus a true rate of 23% in the control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are unadjusted; Hochberg’s adjustment for multiple comparisons was used to maintain the overall 0.05 significance level in test of superiority using the Cochran-Mantel-Haenszel test.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.139</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The noninferiority of PEG 1.5 mcg/kg*24 weeks with respect to PEG 1.5 mcg/kg*48 weeks was to be concluded if the lower bound of the one-sided 95% confidence interval of the difference of the rates (PEG 1.5 mcg/kg*24 weeks minus PEG 1.5 mcg/kg*48 weeks) was greater than the noninferiority margin of -10%.</non_inferiority_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.132</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.198</ci_lower_limit>
            <ci_upper_limit>-0.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBeAg Loss</title>
        <description>HBeAg Loss was tested by assay of Abbott MEIA</description>
        <time_frame>Up to Treatment Week 48</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBeAg Loss</title>
          <description>HBeAg Loss was tested by assay of Abbott MEIA</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.700</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.065</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>-0.008</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBe Seroconversion</title>
        <description>HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>HBe Seroconversion</title>
          <description>HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.598</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.078</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.056</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.112</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.830</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.130</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.136</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.201</ci_lower_limit>
            <ci_upper_limit>-0.071</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) &lt;20,000 IU/mL</title>
        <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test
lowest limit is 6 IU/mL)</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) &lt;20,000 IU/mL</title>
          <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test
lowest limit is 6 IU/mL)</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.135</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.063</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.135</ci_lower_limit>
            <ci_upper_limit>0.009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.139</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.220</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.122</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.191</ci_lower_limit>
            <ci_upper_limit>-0.053</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBV-DNA &lt; 200 IU/mL</title>
        <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBV-DNA &lt; 200 IU/mL</title>
          <description>HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.030</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.072</ci_lower_limit>
            <ci_upper_limit>0.011</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.969</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.044</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.085</ci_lower_limit>
            <ci_upper_limit>-0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBV-DNA Undetectable</title>
        <description>Undetectable HBV-DNA was defined as having a level &lt;6 IU/mL by polymerase chain reaction (PCR).</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBV-DNA Undetectable</title>
          <description>Undetectable HBV-DNA was defined as having a level &lt;6 IU/mL by polymerase chain reaction (PCR).</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.019</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.022</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.019</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.022</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Biochemical Response</title>
        <description>Biochemical response was defined as alanine aminotransferase (ALT) normalization.</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biochemical Response</title>
          <description>Biochemical response was defined as alanine aminotransferase (ALT) normalization.</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.219</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.056</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.071</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.148</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.098</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.174</ci_lower_limit>
            <ci_upper_limit>-0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Combined Response</title>
        <description>Combined response was defined as HBV DNA &lt;20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Combined Response</title>
          <description>Combined response was defined as HBV DNA &lt;20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.995</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.053</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>-0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.389</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.097</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.152</ci_lower_limit>
            <ci_upper_limit>-0.041</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Surface Antigen (HBsAg) Loss</title>
        <description>HBsAg Loss was tested by assay of Abbott MEIA</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Surface Antigen (HBsAg) Loss</title>
          <description>HBsAg Loss was tested by assay of Abbott MEIA</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.013</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.013</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Surface Antigen (HBs) Seroconversion</title>
        <description>HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive</description>
        <time_frame>End of treatment (EOT) and 24 weeks after EOT</time_frame>
        <population>Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Surface Antigen (HBs) Seroconversion</title>
          <description>HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive</description>
          <population>Treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype
Due to zero responses in the 2 arms, pairwise rate difference &amp; corresponding 95% confidence interval were not applicable.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.322</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>End of treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.004</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype
Due to zero responses in the 2 arms, pairwise rate difference &amp; corresponding 95% confidence interval were not applicable.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by genotype</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 weeks after EOT</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.009</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.001</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Liver Biopsy Score</title>
        <description>Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System):
Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis).
Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked [involvement of &gt;2/3 of lobules or nodules]).
Score III (portal inflammation): 0 (none) to 4 (Marked [dense packing of
inflammatory cells in &gt;2/3 of portal tracts]).
Score IV (fibrosis): 0 (none) to 4 (cirrhosis).</description>
        <time_frame>Baseline to 24 weeks after end of treatment</time_frame>
        <population>Treated participants from designated sites</population>
        <group_list>
          <group group_id="O1">
            <title>PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks</title>
            <description>PegIntron 1.0 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O2">
            <title>PEG 1.5 mcg/kg QW * 24 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 24 weeks + 24 weeks follow-up</description>
          </group>
          <group group_id="O3">
            <title>PEG 1.5 mcg/kg QW * 48 Weeks</title>
            <description>PegIntron 1.5 mcg/kg QW * 48 weeks + 24 weeks follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Biopsy Score</title>
          <description>Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System):
Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis).
Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked [involvement of &gt;2/3 of lobules or nodules]).
Score III (portal inflammation): 0 (none) to 4 (Marked [dense packing of
inflammatory cells in &gt;2/3 of portal tracts]).
Score IV (fibrosis): 0 (none) to 4 (cirrhosis).</description>
          <population>Treated participants from designated sites</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="3.06"/>
                    <measurement group_id="O2" value="8.4" spread="2.92"/>
                    <measurement group_id="O3" value="8.2" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.57"/>
                    <measurement group_id="O2" value="-1.7" spread="3.66"/>
                    <measurement group_id="O3" value="-1.6" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>comparison of post-treatment versus baseline values</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>comparison of post-treatment versus baseline values</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>comparison of post-treatment versus baseline values</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.631</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and genotype were the fixed effects and baseline was the covariate.</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and genotype were the fixed effects and baseline was the covariate.</method_desc>
            <param_type>Pairwise rate difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pairwise rate difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Population was all treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>PEG 1.0 mcg/kg QW x24 Weeks</title>
        </group>
        <group group_id="E2">
          <title>PEG 1.5 mcg/kg QW x24 Weeks</title>
        </group>
        <group group_id="E3">
          <title>PEG 1.5 mcg/kg QW x48 Weeks</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR ICTERUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEPATIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>PARATYPHOID FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>THYROID FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGGRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="182" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" events="40" subjects_affected="25" subjects_at_risk="221"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="106" subjects_affected="35" subjects_at_risk="225"/>
                <counts group_id="E2" events="119" subjects_affected="29" subjects_at_risk="221"/>
                <counts group_id="E3" events="153" subjects_affected="42" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="253" subjects_affected="156" subjects_at_risk="225"/>
                <counts group_id="E2" events="316" subjects_affected="158" subjects_at_risk="221"/>
                <counts group_id="E3" events="444" subjects_affected="168" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E3" events="38" subjects_affected="17" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="38" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" events="32" subjects_affected="14" subjects_at_risk="221"/>
                <counts group_id="E3" events="53" subjects_affected="12" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="108" subjects_affected="54" subjects_at_risk="225"/>
                <counts group_id="E2" events="137" subjects_affected="70" subjects_at_risk="221"/>
                <counts group_id="E3" events="206" subjects_affected="77" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" events="44" subjects_affected="21" subjects_at_risk="221"/>
                <counts group_id="E3" events="42" subjects_affected="22" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="116" subjects_affected="47" subjects_at_risk="225"/>
                <counts group_id="E2" events="187" subjects_affected="66" subjects_at_risk="221"/>
                <counts group_id="E3" events="178" subjects_affected="59" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="225"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) agrees not to publish/present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication/presentation to permit the sponsor to review copies of abstracts/manuscripts which report any study results. The sponsor shall have the right to review and comment. If the parties disagree the PI agrees to meet with the sponsor to discuss and resolve.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

